Spike mRNA V2 (Cap1, m1Ψ)
Spike protein of SARS-COV2 sequence has been identified during the pandemic. This Spike mRNA sequence is a synthetic construct HCV1145 Moderna (mRNA-1273) vaccine sequence.
| ￥1500 | |
| RP-A00065-0.2 | |
|
|
|
|
|
|
|
|
|
| ￥1500 | |
| RP-A00065-0.2 | |
|
|
|
|
|
|
|
|
|
Spike protein of SARS-COV2 sequence has been identified during the pandemic. This Spike mRNA sequence is a synthetic construct HCV1145 Moderna (mRNA-1273) vaccine sequence. |
| Form | Liquid |
| Concentration | 1mg/mL |
| Full mRNA length | 4090 nt |
| Full mRNA Molecular Weight | 1.32×10^6 Da |
| Storage buffer | 1mM Sodium citrate, pH 6.5 |
| Storage condition | Store at -20°C for short term (<3 months), store at -80°C for long term. |
| Appearance | Clear and free of foreign particles |
| RNA Length | Expected size band detected |
| RNA Content | Target ± 5% |
| Integrity | ≥ 75% |
| OD260/OD280 | 1.70 ~ 2.30 |
| Capping Efficiency | ≥ 90% |
| Endotoxin | < 10 EU/mg |
| pH | Target ± 0.5 |
| Transfect cells with 2.5μg of mRNA per well (6-well plate) with Lipofectamine™ MessengerMAX™ (or equivalent). 24-48 hours after transfection, detect the expression of Spike protein using flow cytometry analysis with primary antibody against Spike and fluorescent secondary antibody. |
Expression of SARS-CoV-2 spike mRNA in A549 cells. »
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
